Vandana Singh
·
July 14, 2025
Benzinga
AstraZeneca's Phase 3 trial showed baxdrostat lowered systolic blood pressure in treatment-resistant hypertension with a favorable safety profile.
read more
July 16, 2025
June 24, 2025
Financial Times
May 6, 2025
Bloomberg
May 3, 2025
Barchart